Two new studies from the Canadian Centre for Policy Alternatives (CCPA) reveal significant risks and high public costs to the Canadian health care system within the text of the agreement.
(1) The TPP would require Canada to extend patent terms to compensate brand-name pharmaceutical firms for regulatory delays in approving drugs. This policy change could add $636 million annually to the price of drugs in Canada.
Higher drug costs would make pharmacare more costly, and lawsuits from adversely affected drug companies are more likely under TPP’s investor-state dispute settlement mechanism.
(2) TPP investor protections would make it more difficult and costly for Canadian governments to establish new public health programs, including pharmacare, which is on the agenda of ongoing federal-provincial health talks.
“While a strong and balanced international trade regime is critical to Canada’s economic success it should not, and need not, come at the expense of our public health system,” says Sinclair.
Source
No comments:
Post a Comment